Skip to content

ClearPoint Neuro CLPT Other intangible assets—net

Other intangible assets—net at other companies

Boston Scientific logo
Boston ScientificBSX
$7.06B+7.5%
IAR
Integra LifeSciencesIART
$1.11B-6.9%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$69.34M-14.6%
Abbott logo
AbbottABT
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$12.1M+42.9%
Gross profit$7.8M+51.1%
Operating income-$8.5M-37.6%
Net income-$9.6M-58.5%
EPS (diluted)-$0.32-45.5%

Balance sheet

See full
Cash & equivalents$36.5M+195%
Total debt$63.6M+1,750%
Total equity$18.8M-5.7%
Total assets$93.4M+211%

Cash flow

See full
Operating cash flow-$8.0M-29.1%
CapEx$645.0K+252%
Free cash flow-$8.6M-35.5%

Valuation

See full
Market cap$538.61M+69.2%
Enterprise value$565.68M+82.9%
P/S13.3×+3.4×

Profitability

See full
Gross margin62.3%+1.1pp
Operating margin-65.2%-1.9pp
Net margin-71.6%+8.8pp
FCF margin-65.7%+269pp

Returns & leverage

See full
Return on equity-149.7%+4,074pp
Debt / equity3.4×+3.2×
Current ratio5.8×+2.3×

Where this comes from

Reported directly by ClearPoint Neuro in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: ClearPoint Neuro’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about ClearPoint Neuro's other intangible assets—net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ClearPoint Neuro's other intangible assets—net?
ClearPoint Neuro (CLPT) reported other intangible assets—net of $13.42M in Q1 2026.
What does other intangible assets—net mean?
This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.